Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: Considerations of biological relevance of tumour type, data quality and uncertainty assessment

• Published in: Food and chemical toxicology 2014-08, Vol.70, p.264-289
• Main Authors: Edler, Lutz, Hart, Andy, Greaves, Peter, Carthew, Philip, Coulet, Myriam, Boobis, Alan, Williams, Gary M., Smith, Benjamin
• Format: Article
• Language: English
• Subjects: Animals; Benchmark Dose Modelling; Biological and medical sciences; Carcinogenesis, carcinogens and anticarcinogens; Carcinogens - toxicity; Chemical agents; Data selection; Databases, Factual; Disease Models, Animal; DNA Damage - drug effects; Dose-Response Relationship, Drug; Food toxicology; Genotoxic carcinogen; Hazardous Substances - toxicity; Humans; Margin of Exposure; Medical sciences; Models, Biological; Models, Statistical; Neoplasms - chemically induced; Neoplasms - pathology; Reference Standards; Research Design; Risk Assessment; Toxicology; Tumors; Tumour relevance; Uncertainty; Uncertainty assessment
• ISSN: 0278-6915; 1873-6351
• DOI: 10.1016/j.fct.2013.10.030

This article addresses a number of concepts related to the selection and modelling of carcinogenicity data for the calculation of a Margin of Exposure. It follows up on the recommendations put forward by the International Life Sciences Institute – European branch in 2010 on the application of the Margin of Exposure (MoE) approach to substances in food that are genotoxic and carcinogenic. The aims are to provide practical guidance on the relevance of animal tumour data for human carcinogenic hazard assessment, appropriate selection of tumour data for Benchmark Dose Modelling, and approaches for dealing with the uncertainty associated with the selection of data for modelling and, consequently, the derived Point of Departure (PoD) used to calculate the MoE. Although the concepts outlined in this article are interrelated, the background expertise needed to address each topic varies. For instance, the expertise needed to make a judgement on biological relevance of a specific tumour type is clearly different to that needed to determine the statistical uncertainty around the data used for modelling a benchmark dose. As such, each topic is dealt with separately to allow those with specialised knowledge to target key areas of guidance and provide a more in-depth discussion on each subject for those new to the concept of the Margin of Exposure approach.